(Q36631518)

15 August 2017

1 reference

title

Inflammatory bowel disease: Pandora's box, present and future (English)

1 reference

inflammatory bowel diseases

15 August 2017

0 references

1

Jürgen Schölmerich

1 reference

PubMed ID

17057217

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Annals of the New York Academy of Sciences

15 August 2017

1 reference

15 August 2017

1072

1 reference

15 August 2017

365-378

1 reference

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

15 August 2017

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Molecular analysis of commensal host-microbial relationships in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Inflammatory bowel disease and domestic hygiene in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Functional variants of OCTN cation transporter genes are associated with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Genetic variation in DLG5 is associated with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Autoimmunity and apoptosis: the Crohn's connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Biological therapy in IBD. Anti-tumor necrosis factor-alpha and others

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Smoking cessation and the course of Crohn's disease: an intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Are patients with inflammatory bowel disease receiving optimal care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Should adults be screened for celiac disease? What are the benefits and harms of screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Contrasting activity of cytosin–guanosin dinucleotide oligonucleotides in mice with experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Trichuris suis therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.026

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1326.026

1 reference

15 August 2017

1 reference

PubMed ID

17057217